	US 12,201,668 B2
	Adiponectin peptidomimetics formulations
Shikha P Barman, Bedford, MA (US); Kevin L Ward, Arlington, MA (US); and Yugang Chen, Winchester, MA (US)
Assigned to Allysta Pharmaceuticals, Inc., Bellevue, WA (US)
Filed by ALLYSTA PHARMACEUTICALS, INC., San Mateo, CA (US)
Filed on Oct. 24, 2019, as Appl. No. 16/662,932.
Claims priority of provisional application 62/749,861, filed on Oct. 24, 2018.
Prior Publication US 2020/0129585 A1, Apr. 30, 2020
Int. Cl. A61K 38/10 (2006.01); A61K 47/10 (2017.01); A61P 27/02 (2006.01)

CPC A61K 38/10 (2013.01) [A61K 47/10 (2013.01); A61P 27/02 (2018.01)]

9 Claims

1. A composition comprising: a therapeutically effective amount of an adiponectin peptidomimetic having the formula of D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-NH₂, a generally recognized as safe solubilizer, one or more generally recognized as safe surfactants, a buffer comprising boric acid and mannitol; wherein the osmolality is between 260 to 330 mOsm/kg and the pH is between 4.5 to 5.5.